Editorial: To Beam, or Not to Beam-That Is the Question: Reflecting on the Role of Neoadjuvant Radiotherapy in Resectable Pancreatic Cancer.

作者信息

Ye Linda, Molin Marco Dal, He Jin

机构信息

Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

出版信息

Ann Surg Oncol. 2025 Sep 1. doi: 10.1245/s10434-025-18210-y.

DOI:10.1245/s10434-025-18210-y

PMID:40887571

Abstract

摘要

相似文献

[1]

Editorial: To Beam, or Not to Beam-That Is the Question: Reflecting on the Role of Neoadjuvant Radiotherapy in Resectable Pancreatic Cancer.

Ann Surg Oncol. 2025-9-1

[2]

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.

PLoS Med. 2010-4-20

[3]

Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.

Cochrane Database Syst Rev. 2015-4-7

[4]

Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.

PLoS One. 2024

[5]

Comparing upfront surgery with neoadjuvant treatments in patients with resectable, borderline resectable or locally advanced pancreatic cancer: a systematic review and network meta-analysis of randomized clinical trials.

Int J Surg. 2024-6-1

[6]

Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages.

Pancreatology. 2016

[7]

Comparison of the upfront surgery and neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: an updated systematic review and meta-analysis.

Updates Surg. 2024-1

[8]

Neoadjuvant Therapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: A Systemic Review and Meta-Analysis.

J Surg Res. 2025-7

[9]

Optimizing neoadjuvant chemoradiation in resectable and borderline resectable pancreatic cancer: Evidence-based insights.

World J Clin Oncol. 2025-7-24

[10]

Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer.

Cochrane Database Syst Rev. 2016-7-6

本文引用的文献

[1]

Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy.

JAMA Oncol. 2025-4-10

[2]

Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.

Lancet Gastroenterol Hepatol. 2024-3

[3]

Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.

JAMA Oncol. 2022-9-1

[4]

Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy.

Surgery. 2020-1-25

[5]

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

N Engl J Med. 2018-12-20

[6]

Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma.

Ann Surg. 2018-5

[7]

The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysis.

Cancer Med. 2016-10

[8]

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

N Engl J Med. 2011-5-12

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Editorial: To Beam, or Not to Beam-That Is the Question: Reflecting on the Role of Neoadjuvant Radiotherapy in Resectable Pancreatic Cancer.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

本文引用的文献